FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in 20 Years

In a landmark achievement that could transform treatment for thousands of families affected by rare genetic diseases, the FDA has approved AVLAYAH (tividenofusp alfa-eknm), the first medicine designed specifically to cross the blood-brain barrier for Hunter syndrome. This breakthrough represents not only the first new Hunter syndrome treatment in nearly two decades, but the pioneering success of an entirely new class of brain-penetrating biologics.

Hunter syndrome, also known as MPS II, affects approximately 500 Americans and causes severe developmental delays, organ dysfunction, and shortened lifespans due to the buildup of toxic cellular materials in the brain and throughout the body. Until now, existing treatments could address symptoms in other organs but were unable to reach the brain, where much of the damage occurs.

Clinical trials showed remarkable results: 91% reduction in disease biomarkers and 93% of patients achieved normal metabolic levels. For families who have watched their children's development slow and reverse, this approval brings hope that was previously unimaginable.

The therapy's success lies in its innovative design that specifically targets the blood-brain barrier—the protective membrane that normally prevents medicines from reaching brain tissue. This breakthrough could pave the way for treating numerous other neurodegenerative diseases affecting millions worldwide, from Alzheimer's to Parkinson's disease.